Equities
  • Price (EUR)53.00
  • Today's Change0.600 / 1.15%
  • Shares traded1.18k
  • 1 Year change+50.57%
  • Beta0.7031
Data delayed at least 15 minutes, as of Feb 13 2026 16:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Clinica Baviera SA is a Spain-based company engaged in the healthcare sector. The Company focuses on providing services within the field of ophthalmic medicine. The Company is specialized in the diagnosis and treatment of eye disorders, including myopia, hyperopia, astigmatism, cataracts, glaucoma, vitreous-retina and strabismus, among others. The Company operates a network of clinics located in various European countries, such as Spain, Germany, Austria and Italy. The Company is a parent of the Baviera Group, a group that comprises a number of controlled entities, including Clinica Baviera Italia Srl, Clinica Baviera Mallorca SL, Care Vision Germany GmbH and Castellana de Intermediacion Sanitaria SL, among others.

  • Revenue in EUR (TTM)293.69m
  • Net income in EUR40.48m
  • Incorporated1992
  • Employees1.84k
More ▼

Institutional shareholders

8.07%Per cent of shares held by top holders
HolderShares% Held
Independance AM SICAVas of 30 Jun 2025336.95k2.07%
Santander Asset Management SA SGIICas of 31 Dec 2024283.03k1.74%
Janus Henderson Investors UK Ltd.as of 31 Dec 2025199.05k1.22%
Fidelity Management & Research Co. LLCas of 31 Dec 2025192.70k1.18%
Gay-Lussac Gestion SAas of 31 Dec 2024140.00k0.86%
FIL Investments International (Italy)as of 31 Dec 202540.94k0.25%
Ind�pendance AM SAS (France)as of 30 Jun 202537.42k0.23%
Mutuactivos SA SGIICas of 31 Dec 202530.67k0.19%
Fidelity Investments Canada ULCas of 31 Dec 202529.60k0.18%
Lupus alpha Asset Management AGas of 30 Jun 202526.00k0.16%
More ▼
Data from 31 Dec 2024 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.